Covid-19 Mrna (Pfizer) Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.

Usual Adult Dose for COVID-19

0.3 mL IM ONCE, at least 2 months after receiving the last previous dose of COVID-19 vaccine

Comments:

• The US FDA issued a Biologics License Application (BLA) to allow the emergency use of this unapproved product for active immunization to prevent coronavirus disease 2019 (COVID-19). This product is not approved by the US FDA for this use.
• For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Use: Emergency use for the active immunization to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the COVID-19 Omicron variant lineage KP.2

Usual Pediatric Dose for COVID-19

12 years and older: 0.3 mL IM ONCE, at least 2 months after receiving the last previous dose of COVID-19 vaccine

Comments:

• The US FDA issued a BLA to allow the emergency use of this unapproved product for active immunization to prevent COVID-19. This product is not approved by the US FDA for this use.
• For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Use: Emergency use for the active immunization to prevent SARS-CoV-2, including the COVID-19 Omicron variant lineage KP.2

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Patients with a known history of severe allergic reaction to the active component or any of the ingredients
• Patients with a severe allergic reaction (e.g., anaphylaxis) following administration of a COVID-19 vaccine

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For IM administration only. Do not inject IV, intradermally, or subcutaneously.
• Single-dose vial: Invert the vial gently 10 times before withdrawing the dose; do not shake.
• Prefilled syringe: Do not shake syringe; attach a sterile needle prior to administration.

Storage requirements:

• During storage, minimize exposure to room light and avoid exposure to direct sunlight and ultraviolet light.
• Prefilled syringe:
• Do not freeze; discard if product has been frozen.
• If prepared syringes are not used immediately, they must be used within 4 hours of attachment with a sterile needle.
• The total time that syringes may remain unrefrigerated at temperatures between 8C and 25C (46F and 77F) should not exceed 12 hours.

• Single-dose vial storage before use: Consult the manufacturer product information and/or the Fact Sheet for Health Care Providers.
• If frozen, thaw in the refrigerator 2C to 8C (35F to 46F) for up to 2 hours OR at room temperature up to 25C (77F) for up to 30 minutes; the total time that vials may remain unrefrigerated at temperatures between 8C and 25C (46F and 77F) must not exceed 12 hours.
• Store refrigerated between 2C and 8C (36F and 46F) for up to 10 weeks.
• Once withdrawn from the vial, the dose should be immediately administered.
• Do not refreeze thawed vials.

Reconstitution/preparation techniques:

• Vials and prefilled syringes should not be diluted prior to use.
• The manufacturer product information should be consulted.

General:

• This information pertains only to the vaccine product supplied in a single-dose vial OR prefilled syringe with a gray label border stating "2024-2025 Formula."
• Each dose must contain 0.3 mL of vaccine.
• This vaccine does not contain preservatives.

Patient advice:

• To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer